Lisova, Ksenia
Wang, Jia
Hajagos, Tibor Jacob
Lu, Yingqing
Hsiao, Alexander
Elizarov, Arkadij
van Dam, R. Michael
Funding for this research was provided by:
National Cancer Institute (R33 CA240201)
National Institute of Mental Health (R44 MH097271)
National Institute of Biomedical Imaging and Bioengineering (T32 EB002101)
Article History
Received: 8 June 2021
Accepted: 26 August 2021
First Online: 19 October 2021
Competing interests
: The Regents of the University of California have licensed technology to SOFIE, Inc. that was invented by Dr. van Dam, and have taken equity in SOFIE as part of the licensing transaction. Dr. van Dam is a founder and consultant of SOFIE, Inc. Drs. Hajagos and Elizarov are employees of Trace-Ability, Inc. Dr. Hsiao was an employee of SOFIE, Inc. at the time the work was performed.